J. Enas

发表

Vaxfectin™-Formulated Influenza DNA Vaccines Encoding NP and M2 Viral Proteins Protect Mice against Lethal Viral Challenge

Larry R. Smith, D. Kaslow, A. Rolland, 2007, Human vaccines.

Synergy between cationic lipid and co-lipid determines the macroscopic structure and transfection activity of lipoplexes.

M. Ferrari, C. Wheeler, D. Rusalov, 2002, Nucleic acids research.

Trends in lipoplex physical properties dependent on cationic lipid structure, vehicle and complexation procedure do not correlate with biological activity.

M. Ferrari, C. Wheeler, D. Rusalov, 2001, Nucleic acids research.

Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization.

M. Ferrari, C. Wheeler, L. Sukhu, 2001, Vaccine.

Physical characterization and in vivo evaluation of poloxamer‐based DNA vaccine formulations

A. Nanci, A. Rolland, Ji-Hyun Yi, 2008, The journal of gene medicine.

In vivo imaging of the 5-hydroxytryptamine reuptake site in primate brain using single photon emission computed tomography and [123I]5-iodo-6-nitroquipazine.

W. Jagust, J. Eberling, C. Mathis, 1993, European journal of pharmacology.

Binding Potency of 6‐Nitroquipazine Analogues for the 5‐Hydroxytryptamine Reuptake Complex

C. Mathis, C. Mathis, S. E. Taylor, 1994, The Journal of pharmacy and pharmacology.

[125I]5-iodo-6-nitro-2-piperazinylquinoline: a potent and selective ligand for the serotonin uptake complex.

C. Mathis, S. E. Taylor, A. Biegon, 1992, European journal of pharmacology.

Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens.

M. Ferrari, C. Wheeler, L. Sukhu, 2001, Vaccine.

Studies on vitamin D (calciferol) and its analogs. 37. A-Homo-11-hydroxy-3-deoxy vitamin D: ring size and .pi.-facial selectivity effects on the [1,7]-sigmatropic hydrogen shift of previtamin D to vitamin D

J. Palenzuela, W. Okamura, J. Enas, 1991 .

Binding Potency of Paroxetine Analogues for the 5‐Hydroxytryptamine Uptake Complex *

C. Mathis, J. Gerdes, S. Peroutka, 1992, The Journal of pharmacy and pharmacology.

Synthesis of 123I‐and labelled 5‐iodo‐6‐nitroquipazine

C. Mathis, S. Hanrahan, E. Akgün, 1994 .

[125I]5-iodo-6-nitroquipazine: a potent and selective ligand for the 5-hyfroxytryptamine uptake complex. I. In vitro studies

C. Mathis, A. Biegon, Scott E. Taylor, 1993, Brain Research.

Nucleophilic aromatic substitution reactions with the fluoride ion : formation of 5-fluoro-indanones and indandiones related to atipamezole

C. Mathis, J. Gerdes, J. Enas, 1993 .

Mitochondrial avid radioprobes. Preparation and evaluation of 7'(Z)-[125I]iodorotenone and 7'(Z)-[125I]iodorotenol.

H. VanBrocklin, J. O’Neil, S. Hanrahan, 2006, Nuclear medicine and biology.

Synthesis of [11C]atipamezole, a potential PET ligand for the α2-adrenergic receptor in the brain

C. Crouzel, Y. Bramoullé, F. Dollé, 2002 .

Carbon‐11 labelling of the α‐2 antagonist atipamezole

C. Crouzel, Y. Bramoullé, F. Dollé, 2001 .

[F-18]Fluorodihydrorotenone: Synthesis and evaluation of a mitochondrial electron transport chain (ETC) complex I probe for PET

H. VanBrocklin, S. Hanrahan, J. Enas, 1994 .